Amgen - AMGN Stock Forecast, Price & News

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Analyst Ratings Changes

Several analysts have commented on AMGN shares. Morgan Stanley boosted their price target on shares of Amgen from $239.00 to $253.00 and gave the stock an "equal weight" rating in a research note on Friday, July 15th. StockNews.com downgraded shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 8th. Piper Sandler upped their target price on shares of Amgen from $260.00 to $265.00 and gave the stock an "overweight" rating in a research note on Friday, August 5th. Oppenheimer restated a "buy" rating and issued a $290.00 target price on shares of Amgen in a research note on Wednesday, August 10th. Finally, Atlantic Securities lowered their price target on shares of Amgen from $190.00 to $182.00 and set an "underweight" rating for the company in a research report on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $245.14.

Amgen Trading Up 1.1 %

Shares of AMGN Stock opened at $251.08 on Tuesday. The company has a debt-to-equity ratio of 14.76, a quick ratio of 1.17 and a current ratio of 1.53. The stock has a market capitalization of $134.31 billion, a P/E ratio of 21.28, a price-to-earnings-growth ratio of 2.01 and a beta of 0.56. The company has a 50 day moving average price of $244.90 and a 200 day moving average price of $240.96. Amgen has a fifty-two week low of $198.64 and a fifty-two week high of $258.45.

Amgen (NASDAQ:AMGN - Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The medical research company reported $4.65 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.25. Amgen had a net margin of 24.92% and a return on equity of 218.34%. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.53 billion. During the same quarter in the previous year, the firm earned $4.38 EPS. The company's revenue was up 1.0% compared to the same quarter last year. Equities research analysts predict that Amgen will post 17.42 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 8th. Investors of record on Thursday, August 18th will be paid a $1.94 dividend. The ex-dividend date is Wednesday, August 17th. This represents a $7.76 dividend on an annualized basis and a yield of 3.09%. Amgen's payout ratio is 65.76%.

Insider Activity at Amgen

In other Amgen news, Director R Sanders Williams sold 600 shares of the company's stock in a transaction dated Monday, May 23rd. The shares were sold at an average price of $250.00, for a total value of $150,000.00. Following the transaction, the director now directly owns 5,501 shares in the company, valued at approximately $1,375,250. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.46% of the stock is owned by corporate insiders.